Welcome to the international HTA database

Showing [24038 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Point of care testing for human chorionic gonadotropin, creatinine, and blood urea nitrogen: cost-effectiveness
2013	HAYES, Inc.	Home ultraviolet B phototherapy for psoriasis
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	High-sensitivity cardiac troponin for the rapid diagnosis of acute coronary syndrome in the emergency department
2013	National Institute for Health and Care Excellence (NICE)	Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer. NICE technology appraisal guidance 285
2013	NIHR Health Technology Assessment programme	The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No. 150 and part review of technology appraisal No. 118): a systematic review and economic model
2013	Agency for Healthcare Research and Quality (AHRQ)	Testing of CYP2C19 variants and platelet reactivity for guiding antiplatelet treatment
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Tranexamic acid for the management of bleeding: a review of the clinical effectiveness and guidelines
2013	HAYES, Inc.	Musculoskeletal ultrasonography for diagnosis of low back pain
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Components and materials used for total hip replacement: a review of the comparative clinical effectiveness
2013	National Institute for Health and Care Excellence (NICE)	Loxapine inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder (terminated appraisal). NICE technology appraisal guidance 286
2013	Agency for Healthcare Research and Quality (AHRQ)	Evaluation and treatment of tinnitus: comparative effectiveness
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Endovascular therapy for elective and ruptured abdominal aortic aneurysm procedures: a description of utilization trends across Canada
2013	HAYES, Inc.	Outpatient cervical traction for treatment of neck pain
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Knee implant systems: a review of the comparative clinical effectiveness
2013	National Institute for Health and Care Excellence (NICE)	Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism. NICE technology appraisal guidance 287
2013	Agency for Healthcare Research and Quality (AHRQ)	Interventions for adult offenders with serious mental illness
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Codeine and acetylsalicylic acid for the management of post-tonsillectomy or adenoidectomy pain: a review of the clinical evidence
2013	HAYES, Inc.	Percutaneous epidural adhesiolysis for chronic back pain
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Intramuscular oxytocin for the prevention of post-partum hemorrhage outside the hospital: clinical evidence and guidelines
2013	National Institute for Health and Care Excellence (NICE)	Dapagliflozin in combination therapy for treating type 2 diabetes. NICE technology appraisal guidance 288
2013	Agency for Healthcare Research and Quality (AHRQ)	Treatments for seasonal allergic rhinitis
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Antimicrobial ointments for patients undergoing hemodialysis: a review of evidence-based guidelines
2013	HAYES, Inc.	Postoperative intensity-modulated radiation therapy for sinus cancers
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Warming of amniofluid: safety
2013	National Institute for Health and Care Excellence (NICE)	Mirabegron for treating symptoms of overactive bladder. NICE technology appraisal guidance 290
2013	Institut national d'excellence en sante et en services sociaux (INESSS)	[Advisability of expanding the Québec newborn blood screening program]
2013	Agency for Healthcare Research and Quality (AHRQ)	Treatment of atrial fibrillation
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Single-use versus single patient-use electric breast pump kits for the prevention of hospital-acquired infections in mothers and newborns: comparative safety
2013	HAYES, Inc.	Postoperative intra-articular viscosupplementation for treatment of knee conditions
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Point of care testing compared to laboratory testing for the assessment of white blood cell counts and differentials: a review of the clinical effectiveness, diagnostic precision and accuracy, cost-effectiveness, and guidelines
2013	National Institute for Health and Care Excellence (NICE)	Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder. NICE technology appraisal guidance 292
2013	Agency for Healthcare Research and Quality (AHRQ)	Screening for Methicillin-Resistant Staphylococcus Aureus (MRSA)
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Management of childbirth by midwives: clinical evidence and guidelines
2013	HAYES, Inc.	Radiesse voice injectable implant (Merz Aesthetics Inc.) for treatment of glottic insufficiency including vocal cord paralysis
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Frequency of blood pressure measurements for children and adults: evidence-based guidelines
2013	National Institute for Health and Care Excellence (NICE)	Eltrombopag for treating chronic immune thrombocytopenia. NICE technology appraisal guidance 293
2013	Agency for Healthcare Research and Quality (AHRQ)	Local nonsurgical therapies for stage 1 and symptomatic obstructive non–small-cell lung cancer
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	External devices for cervical spine immobilization in the pre-hospital setting: clinical effectiveness
2013	HAYES, Inc.	Remicade (infliximab; Janssen Biotech Inc.) for first-line treatment of pediatric crohn's disease
2013	Blue Cross Blue Shield Association (BCBS)	Percutaneous left atrial appendage closure therapy for the prevention of stroke
2013	National Institute for Health and Care Excellence (NICE)	Aflibercept solution for injection for treating wet age-related macular degeneration. NICE technology appraisal guidance 294
2013	Agency for Healthcare Research and Quality (AHRQ)	Migraine in children: preventive pharmacologic treatments
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Removal of intravenous lines following outpatient day procedures: guidelines
2013	HAYES, Inc.	Robotically assisted mitral valve repair using the da Vinci surgical system (Intuitive Surgical Inc.)
2013	National Institute for Health and Care Excellence (NICE)	Ocriplasmin for treating vitreomacular traction. NICE technology appraisal guidance 297
2013	Agency for Healthcare Research and Quality (AHRQ)	Migraine in adults: preventive pharmacologic treatments
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Ferumoxytol versus other intravenous iron therapies for anemia: a review of the clinical and cost-effectiveness and guidelines
2013	HAYES, Inc.	S-ICD (Subcutaneous Implantable Cardioverter Defibrillator; Boston Scientific Corp.) for prevention of sudden cardiac death
2013	Blue Cross Blue Shield Association (BCBS)	Noninvasive prenatal cell-free fetal DNA-based screening for aneuploidies other than trisomy 21
2013	National Institute for Health and Care Excellence (NICE)	Ranibizumab for treating choroidal neovascularisation associated with pathological myopia. NICE technology appraisal guidance 298
2013	Agency for Healthcare Research and Quality (AHRQ)	Oral contraceptive use for the primary prevention of ovarian cancer
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Intravenous ketamine for the treatment of pain syndromes: clinical effectiveness
2013	HAYES, Inc.	Single-Incision Laparoscopic Surgery (SILS) for hysterectomy for benign disease
2013	National Institute for Health and Care Excellence (NICE)	Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people. NICE technology appraisal guidance 300
2013	Agency for Healthcare Research and Quality (AHRQ)	Bariatric surgery and nonsurgical therapy in adults with metabolic conditions and a body mass index of 30.0 to 34.9 kg/m2
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Nabilone for chronic pain: clinical effectiveness, safety, and guidelines
2013	HAYES, Inc.	Solesta (Q-Med AB) for treatment of fecal incontinence
2013	National Institute for Health and Care Excellence (NICE)	Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy. NICE technology appraisal guidance 301
2013	Agency for Healthcare Research and Quality (AHRQ)	Pharmacologic and mechanical prophylaxis of venous thromboembolism among special populations
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Nabilone for nausea or vomiting not related to chemotherapy: clinical effectiveness and safety
2013	HAYES, Inc.	Stelara (ustekinumab; Janssen Biotech Inc.) for treatment of psoriatic arthritis
2013	National Institute for Health and Care Excellence (NICE)	Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal). NICE technology appraisal guidance 302
2013	Agency for Healthcare Research and Quality (AHRQ)	Treatment strategies for patients with peripheral artery disease
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Portable bone mineral density scanners for screening and diagnosis of osteoporosis: uses, limitations, and guidelines
2013	HAYES, Inc.	Transarterial embolization with embozene microspheres (CeloNova BioSciences Inc.) for treatment of hepatocellular carcinoma and other liver tumors
2013	Institut national d'excellence en sante et en services sociaux (INESSS)	[Use of medullary neurostimulators for the treatment of chronic non-cancer pain]
2013	Scottish Health Technologies Group (SHTG)	Does the addition of positron emission tomography/computed tomography (PET/CT) to the routine investigation and assessment of patients with melanoma yield clinical and economic benefits?
2013	Agency for Healthcare Research and Quality (AHRQ)	Local therapies for unresectable primary hepatocellular carcinoma
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	The prevention of blood-borne infection transmission during immunization: clinical evidence and guidelines
2013	HAYES, Inc.	Triangle tilt surgery for treatment of obstetric brachial plexus injury
2013	Scottish Health Technologies Group (SHTG)	Open, laparoscopic and robot-assisted laparoscopic radical prostatectomy for localised prostate cancer.
2013	Agency for Healthcare Research and Quality (AHRQ)	Wireless motility capsule versus other diagnostic technologies for evaluating gastroparesis and constipation: a comparative effectiveness review
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	The use of spine boards in the pre-hospital setting for the stabilization of patients following trauma: a review of the clinical evidence and guidelines
2013	HAYES, Inc.	VersaJet II hydrosurgery system (Smith & Nephew Inc.) for treatment of burns
2013	Agency for Healthcare Research and Quality (AHRQ)	Interventions to modify health care provider adherence to asthma guidelines
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	The emotional freedom technique for the treatment of post-traumatic stress disorder, depression, or anxiety: clinical evidence
2013	HAYES, Inc.	Vision therapy for convergence insufficiency and accommodative dysfunction in children
2013	Agency for Healthcare Research and Quality (AHRQ)	Pressure ulcer treatment strategies: comparative effectiveness
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Pentazocine versus short-acting opioids for chronic or acute pain: a review of the clinical effectiveness
2013	HAYES, Inc.	Xofigo (radium-223 dichloride; Bayer HealthCare Pharmaceuticals Inc.) for treatment of bone metastases in castration-resistant prostate cancer
2013	Agency for Healthcare Research and Quality (AHRQ)	Pressure ulcer risk assessment and prevention: comparative effectiveness
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Protease inhibitor use for chronic hepatitis C infection in prior null responders and recurrent hepatitis C infection post liver transplant: a review of the clinical evidence
2013	Agency for Healthcare Research and Quality (AHRQ)	Otitis media with effusion: comparative effectiveness of treatments
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Timing of enoxaparin administration for the prophylaxis of venous thromboembolism: clinical evidence and guidelines
2013	NIHR Health Technology Assessment programme	Birmingham and Lambeth Liver Evaluation Testing Strategies (BALLETS): a prospective cohort study
2013	Agency for Healthcare Research and Quality (AHRQ)	Interventions to improve cardiovascular risk factors in people with serious mental illness
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Single-bed versus multi-bed rooms for the prevention of hospital acquired infections: clinical effectiveness and guidelines
2013	Agency for Healthcare Research and Quality (AHRQ)	Child exposure to trauma: comparative effectiveness of interventions addressing maltreatment
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Precautionary period for the safe handling of excreta or body fluids in patients receiving cytotoxic or antineoplastic therapy: clinical evidence and guidelines
2013	Agency for Healthcare Research and Quality (AHRQ)	Interventions for the prevention of Posttraumatic Stress Disorder (PTSD) in adults after exposure to psychological trauma
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Low-molecular weight heparins versus warfarin for the long-term prevention or treatment of deep vein thrombosis or pulmonary embolism: a review of the clinical and cost-effectiveness
2013	Agency for Healthcare Research and Quality (AHRQ)	PCA3 testing for the diagnosis and management of prostate cancer
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Retesting patients with sleep apnea: guidelines and recommendations
2013	NIHR Health Technology Assessment programme	Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette-Guérin vaccination against tuberculosis
2013	Agency for Healthcare Research and Quality (AHRQ)	Allergen-specific immunotherapy for the treatment of allergic rhinoconjunctivitis and/or asthma: comparative effectiveness review
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Hydroxyethyl starch versus other plasma volume expanders: a review of the clinical and cost-effectiveness, and guidelines for use
2013	Agency for Healthcare Research and Quality (AHRQ)	Strategies to prevent weight gain among adults
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Forced air warming units for adults undergoing surgery: clinical evidence
2013	Agency for Healthcare Research and Quality (AHRQ)	Primary care management of abnormal uterine bleeding
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Low molecular weight heparins versus new oral anticoagulants for long-term thrombosis prophylaxis and long-term treatment of DVT and PE: a review of the clinical and cost-effectiveness